HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi)

Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).

规格	价格/CNY		货期	数量
100 μg	￥ 3,109	待询
1 mg	￥ 20,780	待询

规格

价格/CNY

货期

数量

100 μg

￥ 3,109

待询

1 mg

￥ 20,780

待询

产品描述

种属	Human
表达系统	HEK293
标签	C-His-Avi
蛋白编号	A0A140T913(HLA-A*02:01)&P61769(B2M)&FLLTRILTI peptide
别名	MHC, Hepatitis B virus, HBV
蛋白构建	Recombinant Human HBV(HLA-A02:01) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-A02:01),Ile21-Met119(B2M) and FLLTRILTI peptide.[Accession \|A0A140T913(HLA-A*02:01)&P61769(B2M)&FLLTRILTI peptide]
蛋白纯度	> 95% as determined by Tris-Bis PAGE; > 93% as determined by HPLC

内毒素	Less than 1EU per μg by the LAL method.
缓冲液	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
复溶方法	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
存储	-20 to -80°C for 12 months as supplied from date of receipt.-20 to -80°C for 3-6 months in unopened state after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
运输方式	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
研究背景	Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).